| QUESTION | ANSWER |
|---|---|
| What is the **YORVIPATH® pregnancy study**? | The **YORVIPATH® pregnancy study** is aimed to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.[1] |
| What is the study population of the **YORVIPATH® pregnancy study**? | The **YORVIPATH® pregnancy study** includes participants age 15-50 years who were exposed to at least one dose of YORVIPATH at any time within 15 days prior to conception or during pregnancy. Prospective and retrospective pregnancies may be reported.[1] |
| What is the treatment in the **YORVIPATH® pregnancy study**? | In the **YORVIPATH® pregnancy study**, participants will receive palopegteriparatide prescribed as per normal clinical practice.[1] |
| What is the study duration of the **YORVIPATH® pregnancy study**? | Participants will be monitored for 21 months while receiving palopegteriparatide prescribed as per normal clinical practice.[1] |
| What are the objectives of the **YORVIPATH® pregnancy study**? | The primary outcome measures of the **YORVIPATH® pregnancy study** are to evaluate:<br>• The number of fetuses as reported by HCP<br>• Pregnancy outcomes<br>  ○ Live birth (preterm delivery, full-term delivery)<br>  ○ Spontaneous abortion<br>  ○ Pregnancy termination<br>  ○ Fetal death/stillbirth<br>  ○ Molar or ectopic pregnancy<br>• Number of congenital malformations identified in the developing fetus, neonate, or infant<br>• Descriptive statistics of adverse events (AEs), including serious adverse events (SAEs)<br>• Number of hospitalizations including reasons for hospitalization<br>• Descriptive statistics of growth and development milestones as described by the Centers for Disease Control and Prevention (CDC 2021) or other accepted standard assessment<br>• Number of signs of hypocalcemia or hypercalcemia<br>• Descriptive statistics of infant developmental deficiency (CDC 2021)<br>• Descriptive statistics of postnatal growth deficiency or failure to thrive (FTT)<br>• Descriptive statistics of neonatal and infant mortality<br>• Maternal complications of pregnancy – including but not limited to<br>  ○ Premature rupture of membranes (PROM)<br>  ○ Preterm PROM (PPROM)<br>  ○ Pre-eclampsia<br>  ○ Gestational hypertension<br>  ○ Eclampsia<br>  ○ Proteinuria<br>  ○ Gestational diabetes<br>  ○ Intrauterine growth restriction (IUGR)<br>  ○ Polyhydramnios<br>  ○ Preterm delivery<br>  ○ Measures of fetal growth deficiency (e.g., small for gestational age)<br>• Other maternal events of interest - Number of<br>  ○ AEs, including SAEs<br>  ○ Events specific to hypoparathyroidism (e.g., hypercalcemia, hypocalcemia). Serum calcium concentrations at each trimester (if available) and at birth |
| What is eligibility criteria needed in order to participate in the **YORVIPATH® pregnancy study**? | **Inclusion Criteria**[1]<br>Participants aged 15 to 50 years<br>Participants with exposure to at least one dose of YORVIPATH at any time within 15 days prior to conception and/or during pregnancy. The timeframe of 15 days prior to conception is calculated based on 5 times the YORVIPATH half-life of ~ 60 hours<br>Participants providing written informed consent, verbal consent, or eConsent (depending on country regulations) and a Medical Release of Information. For adolescents under the age of majority, verbal or written informed assent by the pregnant minor (where applicable) and verbal or written informed consent by the parent/legal guardian will be obtained.<br><br>**Exclusion Criteria**[1]<br>1. Pregnancies in which only the male partner is exposed to at least one dose of YORVIPATH. |

1. A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding. ClinicalTrials.gov identifier: NCT07345494. Updated January 15, 2026. Accessed January 16, 2026. https://clinicaltrials.gov/study/NCT07345494?term=asnd0043&rank=1

| QUESTION | ANSWER |
|---|---|
| What are the expected timelines (study start, primary completion, study completion) for the **YORVIPATH® pregnancy study**? | The estimated study start date for the **YORVIPATH® pregnancy study** is January 2026.[1]<br><br>The estimated primary completion date for the **YORVIPATH® pregnancy study** is January 2036.[1]<br><br>The estimated study completion date for the **YORVIPATH® pregnancy study** January 2036.[1] |
| Who should I contact for information on enrollment, referrals, or study locations regarding the **YORVIPATH® pregnancy study**? | For questions about participating in the **YORVIPATH® pregnancy study** or to inquire about study locations, please email yorvipathpregnancy@ubc.com or call 877-229-2184 for more information.[1] |

1. A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding. ClinicalTrials.gov identifier: NCT07345494. Updated January 15, 2026. Accessed January 16, 2026. https://clinicaltrials.gov/study/NCT07345494?term=asnd0043&rank=1